Myovant Sciences Ltd.
DelistedCIK 1679082fmd_1EC6JVHZ3QKJPQ7VFCDN37XEZKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2016 to Dec 31, 2022, 27 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 0 | 59 | 231 |
| Research and development | 44 | 117 | 223 | 193 | 137 | 107 |
| Selling, general and administrative | – | – | 42 | 82 | 181 | 259 |
| Total operating expenses | 56 | 141 | 265 | 275 | – | – |
| Operating income | (84) | (143) | (265) | (275) | (261) | (187) |
| Interest expense | 0 | 2 | 9 | 13 | 10 | 14 |
| Interest and investment income | 0 | 0 | 1 | 3 | 0 | 0 |
| Other non-operating income (expense) | (0) | 0 | (0) | 2 | – | – |
| Income before taxes | (84) | (143) | (273) | (288) | (255) | (201) |
| Income tax expense | (0) | 0 | 0 | 1 | 0 | 5 |
| Net income from continuing operations | (83) | (143) | (274) | (289) | (255) | (206) |
| Net income | (83) | (143) | (274) | (289) | (255) | (206) |